Breaking News Instant updates and real-time market news.

BLK

BlackRock

$401.61

1.74 (0.44%)

, IVZ

Invesco

$22.00

0.74 (3.48%)

12:13
10/20/18
10/20
12:13
10/20/18
12:13

Fund companies sued by own employees over pricey 401k plans, Barron's says

BlackRock (BLK), Fidelity, Invesco (IVZ) and T. Rowe Price (TROW) are battling class-action suits related to fund selection and oversight of their 401k plans, and they are not alone as more than 128 cases have been filed since 2016, including Charles Schwab (SCHW), M&T Bank (MTB), Morgan Stanley (MS), Neuberger Berman, and JPMorgan (JPM), Daren Fonda writes in this week's edition of Barron's. While they must abide by regulatory and legal standards aimed at preventing self-dealing, fund companies tend to load plans almost exclusively with their own funds and related investments, the suits state. Regardless of whether these cases have merit, they show that 401k investors often pay steep fees for funds sold by their employers that do not produce better returns than low-cost index funds, Fonda notes. Reference Link

BLK

BlackRock

$401.61

1.74 (0.44%)

IVZ

Invesco

$22.00

0.74 (3.48%)

TROW

T. Rowe Price

$100.13

0.31 (0.31%)

SCHW

Charles Schwab

$46.81

0.11 (0.24%)

MTB

M&T Bank

$162.72

2.09 (1.30%)

MS

Morgan Stanley

$46.43

0.4 (0.87%)

JPM

JPMorgan

$107.92

-0.21 (-0.19%)

  • 21

    Oct

  • 24

    Oct

  • 26

    Feb

BLK BlackRock
$401.61

1.74 (0.44%)

10/17/18
DBAB
10/17/18
NO CHANGE
Target $475
DBAB
Buy
BlackRock core revenue growth is slowing, says Deutsche Bank
Deutsche Bank analyst Brian Bedell says that while BlackRock remains the "best franchise" in asset management, its core revenue growth is slowing. He expects this to persist amid a likely slower future pace of organic growth and fee pressure from mix shift toward more appealing lower cost products. The analyst lowered his price target for BlackRock to $475 from $550 following yesterday's Q3 results but keeps a Buy rating on the name.
10/17/18
SBSH
10/17/18
NO CHANGE
Target $500
SBSH
Buy
BlackRock price target lowered to $500 from $550 at Citi
Citi analyst William Katz lowered his price target for BlackRock to $500 saying near-term base fee pressure and elevated macro risk temper his bullish on the shares. However, the analyst left the company's Q3 results confident in its "resilient business model." He believes the core story is intact and keeps a Buy rating on BlackRock.
10/17/18
ARGS
10/17/18
NO CHANGE
Target $535
ARGS
Buy
BlackRock price target lowered to $535 from $620 at Argus
Argus analyst Stephen Biggar lowered his price target on BlackRock to $535 even though the company beat on Q3 earnings, saying that its revenue grew by "only 2%" and its long-term net inflows of $10.6B were the lightest in 10 quarters. The analyst notes that the industry is undergoing a period of weak inflows, with the institutional segment posting equity index outflows due to "trade tensions, emerging market weakness and a steepening yield curve". Biggar keeps his Buy rating on BlackRock longer term, noting that de-risking will eventually subside as the company continues to deliver above-average operating margins.
10/17/18
WELS
10/17/18
NO CHANGE
Target $440
WELS
Market Perform
BlackRock price target lowered to $440 from $510 at Wells Fargo
Wells Fargo analyst Christopher Harris lowered his price target for BlackRock to $440 from $510 after the stock sold off materially likely based on the quarter's revenue, operating income and flow shortfalls and the extent of fee rate degradation. The analyst reiterates a Market Perform rating on the shares.
IVZ Invesco
$22.00

0.74 (3.48%)

09/24/18
SBSH
09/24/18
NO CHANGE
SBSH
Neutral
Citi sees little benefit to Invesco from acquisition of OppenheimerFunds
Citi analyst William Katz's analysis shows little strategic or financial benefit to Invesco buying Massachusetts Mutual Life Insurance's OppenheimerFunds unit. His preliminary work suggests such a deal results in little earnings accretion and no economic value creation. As such, the analyst does not see such a transaction accelerating Invesco's ability to reach its aspirational goal of 3% to 5% long-term NNA growth. Katz keeps a Neutral rating on the shares.
09/24/18
JPMS
09/24/18
NO CHANGE
Target $29
JPMS
Overweight
Invesco investors won't like possible Oppenheimer deal, says JPMorgan
Following press reports that Invesco is in talks to acquire Oppenheimer Funds, JPMorgan analyst Kenneth Worthington says he does not expect investors will like the possible deal. Given negative industry trends, particularly for active management, the threat of further fee compression, outflows and increased demand for investment, investors would need more from an Invesco deal to get excited about the outlook for the stock, Worthington tells investors in a research note. The analyst, however, believes Oppenheimer is a good fit for Invesco in terms of business mix and capabilities and thinks the deal can be 10% accretive, similar to Van Kampen. He keeps an Overweight rating on Invesco with a $29 price target.
10/18/18
FBCO
10/18/18
DOWNGRADE
Target $27
FBCO
Neutral
Invesco downgraded to Neutral from Outperform at Credit Suisse
Credit Suisse analyst Craig Siegenthaler downgraded Invesco to Neutral from Outperform and lowered his price target to $27 from $34.
10/19/18
RBCM
10/19/18
NO CHANGE
Target $30
RBCM
Outperform
Invesco price target lowered to $30 from $35 at RBC Capital
RBC Capital analyst Kenneth Lee lowered his price target on Invesco to $30 after its Q3 earnings came in line, saying the reduced target reflects lower group multiples. The analyst also maintains his Outperform rating and sees the company's acquisition of OppenheimerFunds as a positive in its efforts to "build scale, deepen distribution, and expand specialized investment capability". Lee expects Invesco's "comprehensive" suite of products and services to generate a premium organic growth rate.
TROW T. Rowe Price
$100.13

0.31 (0.31%)

09/07/18
09/07/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Teva (TEVA) downgraded to Neutral from Outperform at Credit Suisse. 2. Vitamin Shoppe (VSI) downgraded to Underweight from Equal Weight at Barclays with analyst Karen Short raising her price target for the shares to $10 from $4. 3. Dover (DOV) downgraded to Market Perform from Outperform at BMO Capital with analyst R. Scott Graham citing valuation. 4. T. Rowe Price (TROW) downgraded to Hold from Buy at Deutsche Bank with analyst Brian Bedell saying through August, trends are worsening for active managers and T. Rowe Price has posted weaker performance relative to peers. 5. Reliance Steel (RS) double downgraded to Underperform from Buy at BofA/Merrill with analyst Timna Tanners saying he is cautious over late cycle earnings. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/06/18
DBAB
09/06/18
DOWNGRADE
Target $118
DBAB
Hold
T. Rowe Price downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Brian Bedell downgraded T. Rowe Price to Hold and lowered his price target for the shares to $118 from $135.
09/07/18
DBAB
09/07/18
DOWNGRADE
Target $118
DBAB
Hold
Deutsche downgrades T. Rowe Price amid worsening active manager trends
Deutsche Bank analyst Brian Bedell last night downgraded T. Rowe Price to Hold from Buy and lowered his price target for the shares to $118 from $135. Thru August, trends are worsening for active managers and T. Rowe Price has posted weaker performance relative to peers, Bedell tells investors in a research note. In contrast, the analyst sees volumes for e-brokers trending well.
10/11/18
DBAB
10/11/18
NO CHANGE
DBAB
Sell
Deutsche Bank closes Sell catalyst call on T. Rowe Price
Deutsche Bank analyst Brian Bedell closed his Sell catalyst call on T. Rowe Price and keeps a Hold rating on the shares. Fund flow data from Morningstar, combined with the company's report on transfers to Collective Investment Trusts, imply that T. Rowe Price's net flows may be negative for Q3 for the first time since Q4 of 2016, Bedell tells investors in a research note. He believes, however, that this is better reflected in the shares at current levels.
SCHW Charles Schwab
$46.81

0.11 (0.24%)

09/19/18
09/19/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. WELLS FARGO UPGRADES TRANSOCEAN TO OUTPERFORM: Wells Fargo analyst Judson Bailey upgraded Transocean (RIG) to Outperform and raised his price target for the shares to $16 from $13. The analyst "significantly" increased his EBITDA and net asset value estimates across the offshore drilling space to reflect increasing demand combined with tightening availability for high spec ultra-deepwater rigs. This is quickly pushing dayrate expectations higher as well as the market value for ultra-deepwater assets, Bailey tells investors. The analyst cites Transocean's deepwater leverage for his upgrade to Outperform. In late morning trading, Transocean was higher by 3.6%. JEFFERIES UPGRADES E-TRADE TO BUY: Jefferies analyst Daniel Fannon upgraded E-Trade (ETFC) to Buy from Hold with an unchanged price target of $65. The stock's current valuation is attractive for the core business while the financial and strategic benefits as a takeout candidate remain intact, Fannon said. His favorite ideas in the group are E-Trade and Charles Schwab (SCHW). In late morning trading, E-Trade was higher by 3.5%. CREDIT SUISSE UPGRADES SUNPOWER: Credit Suisse analyst Michael Weinstein upgraded SunPower (SPWR) to Outperform from Neutral and raised his target price for shares to $10 from $8. Weinstein said the news that its interdigitated back contact solar modules manufactured in Malaysia will be exempted from U.S. import tariffs won't impact 2018 earnings, as the decision doesn't explicitly call out retroactiveness, but sees a benefit to 2019 and 2020 gross profit of $35M-$40M per year vs. prior estimates. In late morning trading, SunPower was higher by 4.7%. MORGAN STANLEY SAYS OIL SERVICES INDUSTRY ATTRACTIVE: Morgan Stanley analyst Connor Lynagh upgraded the oil services, drilling and equipment industry view to attractive, and initiated 14 stocks in the sector, including top Overweight picks Baker Hughes (BHGE), Halliburton (HAL), and Transocean. GUGGENHEIM RAISES NETFLIX PRICE TARGET: Guggenheim analyst Michael Morris raised his price target for Netflix (NFLX) to $420 from $360 and kept a Buy rating on the shares. The analyst believes that Netflix "subscriber penetration will significantly exceed what is implied in the company's current valuation." He thinks the company's Q3 launch of original local-market content in India and upgrades to its user experience will support further upside in the shares.
10/16/18
ARGS
10/16/18
NO CHANGE
Target $69
ARGS
Buy
Charles Schwab Q3 saw 'strong balance sheet and account growth' says Argus
Argus analyst Stephen Biggar kept his Buy rating and $69 price target on Charles Schwab after its Q3 results yesterday that saw earnings and revenue come in line with consensus. The analyst notes that the 19% increase in net revenue accelerated from the 17% pace in Q2, adding that client assets also rose 12% while the balance sheet expansion tracked close to meeting the company's 15% growth target for FY18. Biggar believes that shares of Charles Schwab are "undervalued", trading at 16-times forward earnings but warrant a multiple in the mid-20s.
10/19/18
SBSH
10/19/18
NO CHANGE
SBSH
E-Trade news removes bull case for Ameritrade, Schwab, says Citi
E-Trade (ETFC) last night announced new five-year financial targets and that it will pursue an independent course given higher internal estimates of intrinsic value versus a potential sale, Citi analyst William Katz tells investors in a research note. While the sector has recently sold off, the absence of a sizeable transaction "further removes a bull case thesis" for shares of both TD Ameritrade (AMTD) and Charles Schwab (SCHW), says Katz. Further, he believes the "inaction" also likely leaves open the group to more online pricing pressures and "keeps alive commodization risks." He does not rate E-Trade, has a Neutral rating on Ameritrade and Sell rating on Schwab.
09/25/18
WOLF
09/25/18
INITIATION
Target $54
WOLF
Underperform
Charles Schwab initiated with an Underperform at Wolfe Research
Wolfe Research analyst Steven Chubak initiated Charles Schwab with an Underperform and $54 price target.
MTB M&T Bank
$162.72

2.09 (1.30%)

09/26/18
GSCO
09/26/18
UPGRADE
Target $196
GSCO
Buy
Goldman says rate hikes halfway through, upgrades M&T Bank to Buy
Goldman Sachs analyst Ryan Nash says his firm's economist is calling for six more rate hikes, two in the second half of 2018 and four more through the end of 2020. With six rate hikes in the books, Goldman believes we are half way through the rate rising cycle, Nash tells investors in a research note. The analyst believes some banks will see upside to revenue growth from rates moving higher. Comerica (CMA), Regions Financial (RF), SunTrust (STI), Citizens Financial (CFG) and KeyCorp (KEY) remain top picks for Nash. He also upgraded M&T Bank (MTB) to Buy from Neutral with 15% upside to his $196 price target. The analyst believes M&T will outperform as the benefits of higher rates exceed market expectations.
10/01/18
EVER
10/01/18
UPGRADE
EVER
Outperform
M&T Bank upgraded to Outperform from In Line at Evercore ISI
10/01/18
EVER
10/01/18
UPGRADE
Target $185
EVER
Outperform
Follow-up: M&T Bank upgraded to Outperform on valuation at Evercore ISI
Evercore ISI upgraded M&T Bank to Outperform from In Line with a $185 price target. Analyst John Pancari raised his rating saying the pullback in shares provides a buying opportunity and notes M&T's fundamental outlook remains particularly solid.
09/26/18
GSCO
09/26/18
UPGRADE
GSCO
Buy
M&T Bank upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Ryan Nash upgraded M&T Bank to Buy with a $196 price target. The analyst recommends the shares to position for the second half of the rates cycle.
MS Morgan Stanley
$46.43

0.4 (0.87%)

10/16/18
OPCO
10/16/18
UPGRADE
Target $62
OPCO
Outperform
Oppenheimer upgrades Morgan Stanley to Outperform after 'clean beat'
Oppenheimer analyst Chris Kotowski upgraded Morgan Stanley to Outperform from Perform with a $62 price target following this morning's Q3 results. The stock in morning trading is up 4%, or $1.67, to $45.13. Morgan Stanley continues to perform well, "and the market has not cared about this," Kotowski tells investors in a research note titled "Stock Down, Earnings Up!" The analyst views the Q3 report as a "clean beat" and upped his 2019 earnings per share estimate to $5.17 from $5.04 as a result. Despite a string of estimate upticks, shares of Morgan Stanley are down 25% since early March, Kotowski points out. He thinks the market's attitude that it is late in the cycle and that financial stocks "are not safe at any price" will prove wrong.
09/25/18
WOLF
09/25/18
INITIATION
Target $61
WOLF
Outperform
Morgan Stanley initiated with an Outperform at Wolfe Research
Wolfe Research analyst Steven Chubak initiated Morgan Stanley with an Outperform and $61 price target.
10/02/18
HSBC
10/02/18
DOWNGRADE
HSBC
Hold
Morgan Stanley downgraded to Hold from Buy at HSBC
10/16/18
OPCO
10/16/18
UPGRADE
OPCO
Outperform
Morgan Stanley upgraded to Outperform from Perform at Oppenheimer
JPM JPMorgan
$107.92

-0.21 (-0.19%)

10/16/18
JANY
10/16/18
NO CHANGE
JANY
Buy
Janney Montgomery Scott says On Deck's new unit hints at new bank partnerships
After On Deck Capital (ONDK) announced earlier that it has created a new wholly owned subsidiary, ODX, that will provide technology and other services to banks looking to lend online to small businesses, Janney Montgomery Scott analyst John Rowan said he sees this as the logical step before the company announces one or more new bank partnerships. While he thinks the company's lone existing bank partnership, with JPMorgan (JPM), is not a profit center, Rowan believes that the economics could improve as each new bank partner comes on-board and he thinks ODX could eventually become a profit center for On Deck. He maintains a Buy rating on the stock.
10/03/18
BERN
10/03/18
NO CHANGE
BERN
Amazon to be accelerant of disruption coming for healthcare, says Bernstein
Bernstein analyst Lance Wilkes believes disruption is coming for healthcare and that Amazon (AMZN) will be an accelerant of this disruption. Further, the analyst sees a parallel with the fast changes in health insurance which took place in the 90's, when health insurance changed from 90% indemnity to 80% managed care within ten years. Wilkes thinks Amazon is developing a series of business strategies for entering healthcare market segments, namely directly entering online pharmacy, creating a disruptor in the employer healthcare space through its venture with Berkshire (BRK.A) and JPMorgan (JPM), and entering digital consumer healthcare spaces including using Alexa for consumer engagement and behavior modification.
10/15/18
BMOC
10/15/18
NO CHANGE
Target $124
BMOC
Market Perform
JPMorgan price target raised to $124 from $118 at BMO Capital
BMO Capital analyst James Fotheringham raised his price target on JPMorgan to $124 after its Q3 earnings beat driven by lower than expected loan loss provision. The analyst notes that financials are "cheap again" in spite of the rising interest rates which are positive for net interest margins, better employment which is positive for credit, and regulatory relief which is positive for their capital position. Fotherinham also keeps his Market Perform rating on JPMorgan, saying its two-year forward earnings multiple is "only slightly" below its long-term historical average.
09/25/18
WOLF
09/25/18
INITIATION
Target $140
WOLF
Outperform
JPMorgan initiated with an Outperform at Wolfe Research
Wolfe Research analyst Steven Chubak initiated JPMorgan with an Outperform and $140 price target.

TODAY'S FREE FLY STORIES

SOR

Source Capital

$37.94

0.26 (0.69%)

17:02
11/12/18
11/12
17:02
11/12/18
17:02
Hot Stocks
Source Capital declares $3.20 per share special dividend »

Source Capital declared a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YRD

Yirendai

$15.47

-1.75 (-10.16%)

17:01
11/12/18
11/12
17:01
11/12/18
17:01
Earnings
Yirendai reports Q3 adjusted income per ADS 87c, consensus 52c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

LTM

Latam Airlines

$8.96

-0.39 (-4.17%)

17:00
11/12/18
11/12
17:00
11/12/18
17:00
Hot Stocks
Latam Airlines reports October passenger traffic up 1.5% »

LATAM Airlines Group …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

ETON

Eton Pharmaceuticals

$0.00

(0.00%)

16:53
11/12/18
11/12
16:53
11/12/18
16:53
Syndicate
Eton Pharmaceuticals 3.6M share IPO priced at $6.00 »

National Securities acted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENR

Energizer

$60.18

-1.235 (-2.01%)

16:49
11/12/18
11/12
16:49
11/12/18
16:49
Hot Stocks
Energizer names Patrick Moore chairman of the board »

Energizer Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

ACIU

AC Immune

$8.74

0.01 (0.11%)

16:47
11/12/18
11/12
16:47
11/12/18
16:47
Initiation
AC Immune initiated  »

AC Immune initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KRNT

Kornit Digital

$19.15

-0.88 (-4.39%)

16:47
11/12/18
11/12
16:47
11/12/18
16:47
Earnings
Kornit Digital reports Q3 adjusted EPS 13c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

ZGNX

Zogenix

$40.82

0.05 (0.12%)

16:46
11/12/18
11/12
16:46
11/12/18
16:46
Initiation
Zogenix initiated  »

Zogenix initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

ADMS

Adamas Pharmaceuticals

$11.45

-0.455 (-3.82%)

16:45
11/12/18
11/12
16:45
11/12/18
16:45
Initiation
Adamas Pharmaceuticals initiated  »

Adamas Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 27

    Nov

  • 27

    Nov

AGN

Allergan

$163.82

-1.77 (-1.07%)

16:45
11/12/18
11/12
16:45
11/12/18
16:45
Initiation
Allergan initiated  »

Allergan initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

SAGE

Sage Therapeutics

$121.50

-9.46 (-7.22%)

16:45
11/12/18
11/12
16:45
11/12/18
16:45
Initiation
Sage Therapeutics initiated  »

Sage Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 27

    Nov

  • 19

    Dec

NBIX

Neurocrine

$103.03

-2.18 (-2.07%)

16:44
11/12/18
11/12
16:44
11/12/18
16:44
Initiation
Neurocrine initiated  »

Neurocrine initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

HLUYY

Lundbeck

$0.00

(0.00%)

16:44
11/12/18
11/12
16:44
11/12/18
16:44
Initiation
Lundbeck initiated  »

Lundbeck initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GWPH

GW Pharmaceuticals

$134.48

-3.3 (-2.40%)

16:43
11/12/18
11/12
16:43
11/12/18
16:43
Initiation
GW Pharmaceuticals initiated  »

GW Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

BHVN

Biohaven Pharmaceutical

$36.42

-2.47 (-6.35%)

16:42
11/12/18
11/12
16:42
11/12/18
16:42
Initiation
Biohaven Pharmaceutical initiated  »

Biohaven Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 14

    Nov

  • 27

    Nov

ACAD

Acadia

$18.86

-0.01 (-0.05%)

16:42
11/12/18
11/12
16:42
11/12/18
16:42
Initiation
Acadia initiated  »

Acadia initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

ALKS

Alkermes

$34.70

-2.98 (-7.91%)

16:41
11/12/18
11/12
16:41
11/12/18
16:41
Initiation
Alkermes initiated  »

Alkermes initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 14

    Nov

  • 31

    Jan

GATX

GATX

$76.43

-2.54 (-3.22%)

16:37
11/12/18
11/12
16:37
11/12/18
16:37
Hot Stocks
GATX acquires up to 3,100 railcars for $229M »

GATX Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVGS

Navigator Holdings

$12.03

-0.13 (-1.07%)

16:35
11/12/18
11/12
16:35
11/12/18
16:35
Earnings
Navigator Holdings reports Q3 EPS 1c, consensus (2c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

GRA

W.R. Grace

$63.83

-0.705 (-1.09%)

16:35
11/12/18
11/12
16:35
11/12/18
16:35
Hot Stocks
W.R. Grace to increase price for silica-based, molecular sieve products by 7% »

W. R. Grace will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQH

AXA Equitable

$21.09

-0.355 (-1.66%)

16:34
11/12/18
11/12
16:34
11/12/18
16:34
Hot Stocks
AXA Equitable reports Q3 annualized premiums up 2% »

Reports Q3 operating…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

EQH

AXA Equitable

$21.09

-0.355 (-1.66%)

16:33
11/12/18
11/12
16:33
11/12/18
16:33
Hot Stocks
Breaking Hot Stocks news story on AXA Equitable »

AXA Equitable announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

EQH

AXA Equitable

$21.09

-0.355 (-1.66%)

16:32
11/12/18
11/12
16:32
11/12/18
16:32
Earnings
AXA Equitable reports Q3 adjusted EPS $1.23, consensus 91c »

Reports Q3 revenue $1.08B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

HAL

Halliburton

$34.17

-0.81 (-2.32%)

16:31
11/12/18
11/12
16:31
11/12/18
16:31
Hot Stocks
Halliburton names Lance Loeffler as CFO, Chris Weber to leave company »

Halliburton is pleased to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ELVT

Elevate Credit

$4.11

-0.08 (-1.91%)

16:31
11/12/18
11/12
16:31
11/12/18
16:31
Hot Stocks
Elevate Credit appoints David Peterson Chief Credit Officer »

Elevate Credit announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.